Heavy Metal Poisoning Drugs Global Market Report 2025
상품코드:1769610
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
중금속 중독 치료제 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 7.5%로 성장할 전망이며, 19억 4,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 환경 재해의 발생 증가, 소아용 중금속 해독 치료에 대한 수요 고조, 신흥 시장으로의 확대, 예방 헬스케어 프로그램에 대한 중금속 스크리닝의 편입에 기인할 것으로 보입니다. 이 기간에 예상되는 주요 동향으로는 나노입자 기반 약물 전달 시스템 사용, 선택성이 강화되고 독성이 저감된 킬레이트제 개발, 해독을 위한 유전자 편집과 RNA 요법 용도, 치료 계획을 개별화하기 위한 인공지능(AI) 통합, 중금속 실시간 검출 및 모니터링을 위한 바이오센서 기술의 진보 등이 있습니다.
산업화의 진전은 향후 수년간 중금속 중독 치료제 시장의 성장을 가속할 것으로 예측됩니다. 산업화란 농업 중심의 경제에서 상품이나 서비스의 제조를 중심으로 하는 경제로의 이행을 말합니다. 이 동향은 급속한 도시 개발 및 인프라 확대로 촉진되어 비즈니스 성장과 경제 발전에 유리한 조건을 만들어 내고 있습니다. 중금속 중독 치료제는 근로자의 건강을 지키고 유해물질 노출 위험을 최소화하며 안전규제 준수를 지원함으로써 산업화에 기여하고 최종적으로 생산성 및 직장 안전성을 높입니다. 예를 들면, 2024년 9월, 영국의 정부기관인 국가통계국에 의하면, 2023년의 영국 제조업체의 제품 매상 총액은 5,746억 달러(4,561억 파운드)에 이르렀으며, 2022년의 5,532억 달러(4,389억 파운드)에서 약 217억 달러(172억 파운드)인 3.9% 증가했습니다. 이처럼 산업화의 진전이 중금속 중독 치료제 시장을 전진시키고 있습니다.
중금속 중독 치료제 시장의 주요 기업은 치료 효과의 향상, 부작용 최소화, 유해 금속에 대한 환경 및 직업 노출률 증가에 대처하기 위해 납 중독의 해독제 등 혁신적 치료법의 개발에 주력하고 있습니다. 이 해독제는 일반적으로 킬레이트제이며 혈류의 납과 결합하여 소변에서 배설을 촉진하여 작동합니다. 예를 들어, 2023년 8월 미국 제약회사 라이징 퍼머슈티컬즈는 소아와 성인의 납 중독을 치료하는 데 사용되는 해독제인 칼슘 에데트산이나트륨 주사제를 발표했습니다. 이 주사용 킬레이트제는 혈액과 조직에서 납 농도를 낮추는 효과가 있으며, 납뇌증과 같은 중증 사례의 치료에 특히 중요합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
세계의 중금속 중독 치료제 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 중금속 중독 치료제 시장 : 성장률 분석
세계의 중금속 중독 치료제 시장 실적 : 규모 및 성장(2019-2024년)
세계의 중금속 중독 치료제 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
세계의 중금속 중독 치료제 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 중금속 중독 치료제 시장 : 제품 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
ALN-TMP
데페라시록스
데페록사민 메실레이트
에메라미드
기타 제품 유형
세계의 중금속 중독 치료제 시장 : 용도별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
비소의 독성
크롬의 독성
구리의 독성
납의 독성
기타 용도
세계 중금속 중독 치료제 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
병원
클리닉
재택 헬스케어
중독 정보 센터
세계의 중금속 중독 치료제 시장 : ALN-TMP 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
저분자 간섭 RNA(siRNA)를 이용한 킬레이트 요법
표적 RNA 간섭 메커니즘
정맥내 제형
간철 과잉증 용도
세계의 중금속 중독 치료제 시장 : 디페라시록스 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
경구 정제 제제
분산정(DT)
제네릭 데페라시록스 제품
수혈에 의한 철과잉증
베타 살라 세미아 관련 사용
세계의 중금속 중독 치료제 시장 : 디페록사민 메실레이트 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
근육내 주사
피하 주입 펌프
철중독 긴급 키트
투석 환자에서 알루미늄 중독
소아용 및 성인용 제제
세계의 중금속 중독 치료제 시장 : 에메라미드 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
수은 특이적 킬레이트화
경구 캡슐제
친유성 킬레이트제
환경 독성 물질 노출 용도
치험약
세계의 중금속 중독 치료제 시장 : 기타 제품 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
디메르카프롤(BAL)
디메르캅토숙신산(DMSA)
2,3-디메르캅토-1-프로판술폰산(DMPS)
페니실라민
에틸렌디아민 테트라아세트산이나트륨칼슘(EDTA)
제7장 지역별 및 국가별 분석
세계의 중금속 중독 치료제 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
세계의 중금속 중독 치료제 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
중금속 중독 치료제 시장 : 경쟁 구도
중금속 중독 치료제 시장 : 기업 프로파일
Sun Pharmaceutical Industries Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
Aurobindo Pharma Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
Dr. Reddy's Laboratories Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
Hikma Pharmaceuticals : 개요, 제품 및 서비스, 전략 및 재무 분석
Lupin Pharmaceuticals Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Zydus Cadila
Aristo Pharmaceuticals Pvt. Ltd.
Medopharm Pvt. Ltd.
Cayman Chemical
Recordati Rare Diseases Inc.
Midas Pharma GmbH
EmeraMed Limited
Ambrosia Remedies Pvt. Ltd.
SGPharma Pvt. Ltd.
Nouryon
Actavis Pharma
Captura Biopharma
Hope Pharmaceuticals
HOPO Therapeutics Inc.
Triveni Interchem Pvt. Ltd.
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
중금속 중독 치료제 시장(2029년) : 새로운 기회를 제공하는 국가
중금속 중독 치료제 시장(2029년) : 새로운 기회를 제공하는 부문
중금속 중독 치료제 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
AJY
영문 목차
영문목차
Heavy metal poisoning drugs are chelating agents that treat toxicity caused by metals like lead, mercury, arsenic, and cadmium. These drugs bind to harmful metals in the bloodstream, forming complexes that the body can safely eliminate through urine or feces. Their primary purpose is to lower metal levels in the body and prevent damage to organs.
The main products in this category include ALN-TMP, deferasirox, deferoxamine mesylate, emeramide, and others. ALN-TMP is an experimental RNA interference (RNAi) therapy aimed at reducing the production of specific proteins involved in heavy metal metabolism. It is applied in cases of arsenic, chromium, copper, lead toxicity, among others, and is utilized by hospitals, clinics, home healthcare providers, and poison control centers.
The heavy metal poisoning drugs market research report is one of a series of new reports from The Business Research Company that provides heavy metal poisoning drugs market statistics, including heavy metal poisoning drugs industry global market size, regional shares, competitors with a heavy metal poisoning drugs market share, detailed heavy metal poisoning drugs market segments, market trends and opportunities, and any further data you may need to thrive in the heavy metal poisoning drugs industry. This heavy metal poisoning drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The heavy metal poisoning drugs market size has grown strongly in recent years. It will grow from $1.34 billion in 2024 to $1.45 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth during the historic period can be attributed to increased industrial pollution, higher occupational exposure in the mining and manufacturing sectors, greater awareness and diagnosis of heavy metal toxicity, expanded use of chelation therapy, and the implementation of government regulations focused on environmental and workplace safety.
The heavy metal poisoning drugs market size is expected to see strong growth in the next few years. It will grow to $1.94 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to the increasing occurrence of environmental disasters, rising demand for pediatric heavy metal detoxification treatments, expansion into emerging markets, and the incorporation of heavy metal screening into preventive healthcare programs. Key trends anticipated during this period include the use of nanoparticle-based drug delivery systems, development of chelators with enhanced selectivity and reduced toxicity, application of gene editing and RNA therapies for detoxification, integration of artificial intelligence (AI) to personalize treatment plans, and advancements in biosensor technology for real-time detection and monitoring of heavy metals.
The rising industrialization is anticipated to drive the growth of the heavy metal poisoning drugs market in the coming years. Industrialization refers to the transition of an economy from being primarily agricultural to one centered around the manufacturing of goods and services. This trend is fueled by rapid urban development and infrastructure expansion, which create favorable conditions for business growth and economic advancement. Heavy metal poisoning drugs contribute to industrialization by safeguarding workers' health, minimizing toxic exposure risks, and supporting compliance with safety regulations-ultimately enhancing productivity and workplace safety. For example, in September 2024, the Office for National Statistics, a UK-based government agency, reported that the total value of UK manufacturers' product sales reached $574.6 billion (£456.1 billion) in 2023, an increase of approximately $21.7 billion (£17.2 billion), or 3.9%, from $553.2 billion (£438.9 billion) in 2022. Thus, the growing industrialization is propelling the heavy metal poisoning drugs market forward.
Leading companies in the heavy metal poisoning drugs market are concentrating on the development of innovative treatments, such as antidotes for lead poisoning, to improve therapeutic effectiveness, minimize side effects, and address the growing rates of environmental and occupational exposure to toxic metals. These antidotes, typically chelating agents, work by binding to lead in the bloodstream and facilitating its excretion through urine. For example, in August 2023, Rising Pharmaceuticals, a US-based pharmaceutical firm, introduced edetate calcium disodium injection, an antidote used to treat lead poisoning in both children and adults. This injectable chelating agent is effective in lowering lead levels in the blood and tissues and is particularly vital for treating severe cases like lead encephalopathy.
In October 2024, the Biomedical Advanced Research and Development Authority (BARDA), a U.S.-based research agency, partnered with HOPO Therapeutics to support the development of an oral chelating agent for treating heavy metal poisoning. The goal of this collaboration is to advance HOPO-101 toward approval by the Food and Drug Administration (FDA) as an oral countermeasure for both radioactive and heavy metal exposure, thereby strengthening preparedness for radiological emergencies and addressing broader public health concerns such as lead poisoning. HOPO Therapeutics is a U.S.-based clinical-stage pharmaceutical company focused on developing best-in-class, orally available therapies for heavy metal toxicity.
Major players in the heavy metal poisoning drugs market are Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals, Lupin Pharmaceuticals Inc., Zydus Cadila, Aristo Pharmaceuticals Pvt. Ltd., Medopharm Pvt. Ltd., Cayman Chemical, Recordati Rare Diseases Inc., Midas Pharma GmbH, EmeraMed Limited, Ambrosia Remedies Pvt. Ltd., SGPharma Pvt. Ltd., Nouryon, Actavis Pharma, Captura Biopharma, Hope Pharmaceuticals, HOPO Therapeutics Inc., and Triveni Interchem Pvt. Ltd.
North America was the largest region in the heavy metal poisoning drugs market in 2024. The regions covered in heavy metal poisoning drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the heavy metal poisoning drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The heavy metal poisoning drugs market consists of sales of dithiol chelating agents, aminopolycarboxylic acid chelators, amino acid-derived chelators, and hydroxamic acid derivatives. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Heavy Metal Poisoning Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on heavy metal poisoning drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for heavy metal poisoning drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The heavy metal poisoning drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Product Type: ALN-TMP; Deferasirox; Deferoxamine Mesylate; Emeramide; Other Product Types
2) By Application: Arsenic Toxicity; Chromium Toxicity; Copper Toxicity; Lead Toxicity; Other Applications
3) By End-User: Hospitals; Clinics; Home Healthcare; Poison Control Centers
Subsegments:
1) By ALN-TMP: Small Interfering RNA (siRNA)-Based Chelation Therapies; Targeted RNA Interference Mechanisms; Intravenous Formulations; Hepatic Iron Overload Applications
2) By Deferasirox: Oral Tablet Formulations; Dispersible Tablets (DT); Generic Deferasirox Products; Iron Overload From Blood Transfusions; Beta-Thalassemia Related Use
3) By Deferoxamine Mesylate: Intramuscular Injections; Subcutaneous Infusion Pumps; Iron Poisoning Emergency Kits; Aluminum Toxicity In Dialysis Patients; Pediatric And Adult Formulations
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Heavy Metal Poisoning Drugs Market Characteristics
3. Heavy Metal Poisoning Drugs Market Trends And Strategies
4. Heavy Metal Poisoning Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Heavy Metal Poisoning Drugs Growth Analysis And Strategic Analysis Framework
5.1. Global Heavy Metal Poisoning Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Heavy Metal Poisoning Drugs Market Growth Rate Analysis
5.4. Global Heavy Metal Poisoning Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Heavy Metal Poisoning Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Heavy Metal Poisoning Drugs Total Addressable Market (TAM)
6. Heavy Metal Poisoning Drugs Market Segmentation
6.1. Global Heavy Metal Poisoning Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
ALN-TMP
Deferasirox
Deferoxamine Mesylate
Emeramide
Other Product Types
6.2. Global Heavy Metal Poisoning Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Arsenic Toxicity
Chromium Toxicity
Copper Toxicity
Lead Toxicity
Other Applications
6.3. Global Heavy Metal Poisoning Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Home Healthcare
Poison Control Centers
6.4. Global Heavy Metal Poisoning Drugs Market, Sub-Segmentation Of ALN-TMP, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Small Interfering RNA (siRNA)-Based Chelation Therapies
Targeted RNA Interference Mechanisms
Intravenous Formulations
Hepatic Iron Overload Applications
6.5. Global Heavy Metal Poisoning Drugs Market, Sub-Segmentation Of Deferasirox, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Tablet Formulations
Dispersible Tablets (DT)
Generic Deferasirox Products
Iron Overload From Blood Transfusions
Beta-Thalassemia Related Use
6.6. Global Heavy Metal Poisoning Drugs Market, Sub-Segmentation Of Deferoxamine Mesylate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intramuscular Injections
Subcutaneous Infusion Pumps
Iron Poisoning Emergency Kits
Aluminum Toxicity In Dialysis Patients
Pediatric And Adult Formulations
6.7. Global Heavy Metal Poisoning Drugs Market, Sub-Segmentation Of Emeramide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Mercury-Specific Chelation
Oral Capsule Form
Lipophilic Chelators
Environmental Toxic Exposure Applications
Investigational Therapies
6.8. Global Heavy Metal Poisoning Drugs Market, Sub-Segmentation Of Other Product Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
